For patients with stage II/III tumors, monotherapy with the anti-PD1 agent dostarlimab in a small single-arm phase II study achieved a clinical response rate of 100% (95% CI, 74 to 100), with no evidence of a tumor on magnetic resonance imaging, endoscopic evaluation, digital rectal examination, or biopsy [8]. Here, PDCD1 is linked to neoplasm.